- Mary J Laughlin, Division of Hematology/Oncology, University of Virginia
- Alejandro Lazo-Langner, University of Western Ontario
- Dan L Longo, National Institute on Aging, National Institutes of Health
- Peter O'Donovan, BioMed Central
Grouping together diseaes with the same systemic complications can allow meta-analyses of otherwise sparse microarray datasets.
News from the web
- 16 April 2014
- Revolutionary blood recycling machine developed using Stratasys 3D printing undergoes successful patient trials
- 16 April 2014
- C1s antibody prevents complement-mediated destruction of red blood cells exposed to patient autoantibodies
BMC Hematology is an open access, peer-reviewed journal that considers articles on basic, experimental and clinical research related to hematology. The journal welcomes submissions on non-malignant and malignant hematological diseases, hemostasis and thrombosis, hematopoiesis, stem cells and transplantation.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Hematology and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at firstname.lastname@example.org, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
Section Editor's profile
Dan L. Longo
Dr. Longo is Professor of Medicine at Harvard Medical School in the Division of Hematology at Brigham and Women's Hospital and Deputy Editor of the New England Journal of Medicine. He is a Master of the American College of Physicians and is a member of the American Society of Clinical Investigation and the Association of American Physicians.
He has been active in research on the treatment of malignant lymphoma including new treatments targeting CD30, CD40, HLA Class II molecules and immunoglobulin idiotype. His laboratory work has focused in part on the regulation of lymphocyte proliferation, NK cell effects on hematopoiesis, and tumor-induced immunosuppression.
Dan Longo is the Section Editor of the Malignant hematological diseases section of BMC Hematology. Read more about the key issues in this field and the manuscripts he would like to see submitted to the section in his interview with the journal.
BMC series blog
- 10 April 2014
- Metagenomics: tools, comparisons and many applications
- 09 April 2014
- BMC Nursing – looking forwards, looking back
- 08 April 2014
- Ancient DNA reveals the lion’s past and (perhaps) future
BMC Blood Disorders
BMC Hematology assimilated the Editorial board and history of BMC Blood Disorders on renaming of the journal in 2013. The full archive of BMC Blood Disorders is available here and the rationale and objectives behind the change of journal name are explained in the editorial that accompanied the relaunch.